arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Lantern Pharma Inc.

LTRN
$2.88 ▲ +0.08 (+2.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lantern Pharma Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $32.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -78.1%
FCF / Share $-0.34
Trailing P/E
Price / Book 9.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-3.33M
↑ +26.6%
FCF / Share Free cash flow per share
$-0.34
↑ +17.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters